“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

Silicone breast prostheses, once vital for balance and confidence, now symbolize survival and the complex interplay of joy and sorrow. After cancer, even your closet tells a story you never imagined ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...

Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...

Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...

Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...